6HHO

Crystal structure of RIP1 kinase in complex with GSK547

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.49 Å
  • R-Value Free: 0.227 
  • R-Value Work: 0.208 
  • R-Value Observed: 0.209 

wwPDB Validation   3D Report Full Report


This is version 1.0 of the entry. See complete history. 


Literature

RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer.

Wang, W., Marinis, J.M., Beal, A.M., Savadkar, S., Wu, Y., Khan, M., Taunk, P.S., Wu, N., Su, W., Wu, J., Ahsan, A., Kurz, E., Chen, T., Yaboh, I., Li, F., Gutierrez, J., Diskin, B., Hundeyin, M., Reilly, M., Lich, J.D., Harris, P.A., Mahajan, M.K., Thorpe, J.H., Nassau, P., Mosley, J.E., Leinwand, J., Kochen Rossi, J.A., Mishra, A., Aykut, B., Glacken, M., Ochi, A., Verma, N., Kim, J.I., Vasudevaraja, V., Adeegbe, D., Almonte, C., Bagdatlioglu, E., Cohen, D.J., Wong, K.K., Bertin, J., Miller, G.

(2018) Cancer Cell 34: 757-774.e7

  • DOI: 10.1016/j.ccell.2018.10.006
  • Primary Citation of Related Structures:  
    6HHO

  • PubMed Abstract: 

    • Pancreatic ductal adenocarcinoma (PDA) is characterized by immune tolerance and immunotherapeutic resistance. We discovered upregulation of receptor-interacting serine/threonine protein kinase 1 (RIP1) in tumor-associated macrophages (TAMs) in PDA. To study its role in oncogenic progression, we developed a selective small-molecule RIP1 inhibitor with high in vivo exposure ...

    Pancreatic ductal adenocarcinoma (PDA) is characterized by immune tolerance and immunotherapeutic resistance. We discovered upregulation of receptor-interacting serine/threonine protein kinase 1 (RIP1) in tumor-associated macrophages (TAMs) in PDA. To study its role in oncogenic progression, we developed a selective small-molecule RIP1 inhibitor with high in vivo exposure. Targeting RIP1 reprogrammed TAMs toward an MHCII hi TNFα + IFNγ + immunogenic phenotype in a STAT1-dependent manner. RIP1 inhibition in TAMs resulted in cytotoxic T cell activation and T helper cell differentiation toward a mixed Th1/Th17 phenotype, leading to tumor immunity in mice and in organotypic models of human PDA. Targeting RIP1 synergized with PD1-and inducible co-stimulator-based immunotherapies. Tumor-promoting effects of RIP1 were independent of its co-association with RIP3. Collectively, our work describes RIP1 as a checkpoint kinase governing tumor immunity.

    Organizational Affiliation: 

    S. Arthur Localio Laboratory, Department of Surgery, New York University School of Medicine, 435 East 30th Street, 4th Floor, New York, NY 10016, USA; Department of Cell Biology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA. Electronic address: george.miller@nyumc.org.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Receptor-interacting serine/threonine-protein kinase 1 A, B303Homo sapiensMutation(s): 4 
Gene Names: RIPK1, RIP, RIP1
EC: 2.7.11.1
Find proteins for Q13546 (Homo sapiens)
Explore Q13546 
Go to UniProtKB:  Q13546
NIH Common Fund Data Resources
PHAROS:  Q13546
GTEx:  ENSG00000137275
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
G4W
Query on G4W
Download Ideal Coordinates CCD File 
A, B
6-[4-[(5~{S})-5-[3,5-bis(fluoranyl)phenyl]pyrazolidin-1-yl]carbonylpiperidin-1-yl]pyrimidine-4-carbonitrile
C20 H20 F2 N6 O
PZXPEVAQKNYNRX-SFHVURJKSA-N		 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.49 Å
  • R-Value Free: 0.227 
  • R-Value Work: 0.208 
  • R-Value Observed: 0.209 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 102.649α = 90
b = 130.37β = 90
c = 50.839γ = 90
Software Package:
Software NamePurpose
MOSFLMdata reduction
Aimlessdata scaling
BUSTERrefinement
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2018-12-12
    Type: Initial release